A new partnership has been announced between Blockchain for Impact (BFI) and CSIR- National Chemical Laboratory (NCL), aimed at accelerating translational biomedical research and enabling healthcare impact. At its core, this collaboration is about moving promising science beyond the lab, into pathways that can shape better diagnostics, therapies, and patient outcomes.
The projects being supported under this partnership are geared toward addressing critical disease areas:
• Glioblastoma, through innovative metabolic modulation strategies
• Sickle cell anemia, via next-generation hemoglobin modulators
• Heart failure and osteoarthritis, through development of a biosimilar
By enabling research and facilitating its journey toward application, this partnership seeks to build stronger innovation pipelines within India’s biomedical ecosystem.
In addition, BFI has partnered with the Indian Institute of Science Education and Research (IISER) Pune to further efforts in translating biomedical research.
This collaboration is anchored in advancing a deeper understanding of disease biology. The supported project uses advanced models and analytical techniques to understand how metabolic and immune systems interact, with the aim of identifying new targets for earlier diagnosis and improved treatment of chronic inflammatory liver diseases.
Through this partnership, BFI and IISER Pune seek to strengthen pathways that connect discovery led research with real impact, contributing to effective healthcare solutions.
